Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant tislelizumab plus chemotherapy for initially unresectable stage IIIA/N2 non-small cell lung cancer
ChiCTR2400092229Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab in non-small cell lung cancer (NSCLC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Surgical conversion rate. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
tislelizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400092229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400092229.